- Two branded oral GLP-1 pills now carry FDA approval, Foundayo (orforglipron) and Wegovy Tablets (oral semaglutide).
- Both are daily tablets rather than weekly injections and both work, though the injectables still show larger average weight loss in head-to-head trial data.
- Neither is compounded. Anything sold as compounded semaglutide is a different product with a different risk profile, whatever a med spa website claims.
- Inside our membership the doctor is a flat $299 per month and the medicine, whichever form fits you, is billed by the pharmacy at pharmacy cost with zero markup.
Yes, a real GLP-1 pill exists now. For patients who have put off treatment because they will not inject, that fact changes the conversation and turns it to Foundayo vs Wegovy Tablets. The next question is which tablet fits, what the evidence says and what it costs. Those answers deserve precision over marketing.
What the two branded oral options are
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist from Eli Lilly. The FDA approved it on April 1, 2026 for chronic weight management in adults with obesity or overweight with at least one weight-related condition, based on the phase 3 ATTAIN program. It can be taken at any time of day without food or water restrictions, which is a genuine practical difference from older orals.
Wegovy Tablets is Novo Nordisk's oral formulation of semaglutide, approved for weight management in December 2025. It is a daily tablet taken in the morning on an empty stomach with a small amount of water, then nothing by mouth for about thirty minutes. That ritual matters for absorption and patients who manage it well do very well on it.
Both are branded, FDA-approved medicines. Both are prescribed by our physicians when clinically appropriate, alongside the quarterly Biomarker Audit that guides every dose decision.
How they compare on the details that matter
| Feature | Foundayo (orforglipron) | Wegovy Tablets (oral semaglutide) | Injectable semaglutide or tirzepatide |
|---|---|---|---|
| Approval | April 1, 2026, weight management | December 2025, weight management | Established approvals |
| Dosing | Once daily, any time, no food or water restrictions | Once daily, fasted, thirty-minute wait | Weekly injection |
| Trial program | ATTAIN, more than 3,000 adults | OASIS program | STEP and SURMOUNT programs |
| Average weight loss in pivotal trials | Around 11 to 12 percent at highest doses | Around 15 percent at the 50 mg maintenance dose | Up to about 15 percent on semaglutide in STEP 1 and up to about 22.5 percent on tirzepatide in SURMOUNT-1 |
| Storage | Room temperature | Room temperature | Refrigeration recommended |
| Best fit | Needle-averse, schedule-flexible | Needle-averse, comfortable with a fasted morning routine | Patients prioritizing maximum average weight loss |
We hedge the average weight-loss figures because trial populations differ and individual results vary considerably. What the data supports is a plain statement. The injectables still carry larger average effects in their pivotal trials and the orals trade some of that effect for a needle-free route.
Who each formulation actually fits
The best formulation question is about your life rather than about the molecule rankings. Patients who travel constantly sometimes prefer an injection they take once a week and forget about. Patients with needle aversion sometimes tolerate a thirty-minute fasted wait easily because the trade is worth it to them. Patients with early-morning routines that involve coffee first thing sometimes prefer Foundayo for exactly the opposite reason.
Our clinicians start this conversation with your history, your biomarkers and your actual morning, not with a preference for one product. Because the membership covers the doctor at a flat fee and the pharmacy bills the medicine at cost, the recommendation has no financial tilt. Nobody here earns more because you take one brand over another.


What oral GLP-1s cost, honestly
We will not quote a single inflated price or a single discounted one, because both would be dishonest. Pharmacy pricing for branded GLP-1s changes with manufacturer programs and with the pharmacy. What we can promise is the structure. The medicine is billed by the pharmacy directly at pharmacy cost. There is no markup, no molecule upcharge and no dose-escalation fee from us. The $299 monthly fee is the doctor and the quarterly Biomarker Audit and it stays $299 whether your prescription is a starter dose or a maintenance dose.
Patients coming from programs that bundle the medicine into a subscription often find that structure confusing at first and then refreshingly legible. You can see exactly what the medicine costs, because you pay the pharmacy directly. You can see exactly what the doctor costs, because the fee is flat and posted.
Why we will not prescribe compounded pills
Compounded semaglutide sold as tablets or sublingual drops is not the same product as an FDA-approved medicine. The FDA has raised concerns about unapproved GLP-1 products, including dosing errors in compounded injectable semaglutide and fraudulent products with false labeling. Some compounded products have contained salt forms of semaglutide, which are different active ingredients from the base form in the approved medicines.
Our position is simple and non-negotiable. Branded and FDA-approved only. If a clinic offers you compounded pills at a price that seems too good to be true, the price is not the problem. The product is.
How the first ninety days usually look
A typical start on an oral GLP-1 inside our membership goes like this. The intake visit establishes your baseline Biomarker Audit, including ApoB, Lp(a), hs-CRP, HbA1c, insulin markers and a full hormone and thyroid panel. The prescription, whatever form it takes, is written against that baseline. You begin the starter dose and the clinical team checks in as your body adjusts.
At ninety days the first follow-up audit lands and the dose decision is made from the panel and your experience together. Some patients titrate up. Some hold. Some switch formulations entirely, because a morning-routine conflict or a side effect makes a different form the better clinical answer. All of that sits inside the same flat monthly fee.
Who we built this for
If you have a high-deductible plan you never meet or no plan at all and you have been paying cash for care that never checked a lab, the oral GLP-1 conversation is a reasonable place to start. What separates a durable result from a temporary one is not the tablet versus the injection. It is whether anybody is reading your biomarkers while you lose the weight and keeping the weight off afterward.
That is the part we do and it is the part most cash-pay programs skip.
Frequently asked questions
Is there an FDA-approved GLP-1 pill?
Yes. Foundayo (orforglipron) was approved on April 1, 2026 and Wegovy Tablets (oral semaglutide) in December 2025. Both are branded, FDA-approved medicines for chronic weight management in appropriate adults.
Which works better, Foundayo or Wegovy Tablets?
Both are effective. Pivotal trial averages suggest the highest semaglutide doses produce somewhat larger average weight loss than the orfordose at its approved doses and injectable tirzepatide still shows the largest averages overall. Individual results vary and formulation fit matters as much as the averages.
Do oral GLP-1s work as well as injections?
They work, with somewhat smaller average weight-loss effects in the published trials. The right question is which form you will actually take consistently, because a medicine you take every day beats a stronger one you avoid.
Are compounded GLP-1 pills safe?
We do not prescribe them. The FDA has warned about dosing errors, salt forms and fraudulent labeling in compounded semaglutide products. Branded and FDA-approved medicines are the only GLP-1s our physicians prescribe.
How much does an oral GLP-1 cost per month?
Pharmacy pricing varies by manufacturer program and pharmacy. Inside our membership the medicine is billed by the pharmacy at pharmacy cost with zero markup and you see the price directly. The doctor and the quarterly Biomarker Audit are the flat $299 monthly fee and never change with the dose.
Can I switch from an injectable to an oral GLP-1?
Often yes and sometimes the reverse. The decision follows the panel, your response and your routine. Because we carry both oral and injectable options, the switch is a clinical conversation rather than a sales one.
Do I need to fast before taking Wegovy Tablets?
Yes. Wegovy Tablets are taken in the morning on an empty stomach with a small amount of water and you wait about thirty minutes before eating or drinking anything else. Foundayo has no food or water restrictions.
Will my insurance cover an oral GLP-1?
Coverage varies widely and many plans still do not cover weight-management medicines. Our model is built to work without insurance, which is why the pharmacy bills at cost and the doctor is a flat fee. Patients on high-deductible plans often find the math clearer than an in-network alternative.
Related guides
- Medical weight loss at GoodLife Health
- How to break a GLP-1 weight loss plateau without raising your dose
- The unbundled pharmacy model, explained
- Cardiometabolic optimization: the definitive guide
Sources
- Eli Lilly, FDA approves Foundayo (orforglipron), April 1, 2026
- STEP 1 trial, once-weekly semaglutide in adults with overweight or obesity, NEJM
- SURMOUNT-1, tirzepatide weight loss results, Eli Lilly
- FDA, concerns with unapproved GLP-1 drugs used for weight loss
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/